Eureka 93 Inc. (OTCPK:LXLL.F) confirmed that the Board of Directors has commenced a review of strategic and financing alternatives due to limited capital resources and recent adverse conditions in the public capital markets and CBD isolates market, with a view to identifying a transaction that is in the best interests of shareholders. Alternatives to be explored include joint ventures, mergers, sale of the company, and/or sale of core assets. As part of this strategic review process, Eureka93 is preferentially seeking partners with a consumer product focus supported by technology and R&D, leveraging from its existing GMP nutraceutical manufacturing and R&D facility. While the company has initiated this strategic review process, there is no certainty that any transaction or alternative will be undertaken or pursued. Eureka93 has not set a definitive schedule to complete its evaluation and no decision on any particular transaction or alternative has been reached at this time. In accordance with its continuous disclosure obligations, the company will disclose material developments, if, as and when they occur.